ReviewSleep & breathing = Schlaf & Atmung2025
Prevalence and risk factors of obstructive sleep apnoea in people with sarcoidosis: a narrative review.
Review in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Bioinformatics Methods Were Employed to Investigate Potential Molecular Links Between Obstructive Sleep Apnea and Sarcoidosis.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests a link between sarcoidosis and obstructive sleep apnoea (OSA). Previous studies have reported a high prevalence of OSA in people with sarcoidosis; however, much of this evidence has been derived from retrospective analyses. Recently, prospective cohort studies have provided further insight into potential interactions between sarcoidosis and OSA. This narrative review aims to synthesise current evidence on the prevalence of OSA in people with sarcoidosis and identify associated risk factors.
methodsWe conducted a search of Pubmed, Medline, the Cochrane Library and the Register of Controlled Trials and identified eight studies that evaluated the prevalence of OSA in people with sarcoidosis.
resultsThe prevalence of OSA in sarcoidosis patients ranged from 44% to 88%. Mild OSA was generally more common than moderate to severe OSA, with prevalence rates of 24% to 52% for mild cases and 5% to 51% for moderate to severe cases. Advancing age and elevated body mass index (BMI) were consistently associated with increased OSA risk. Corticosteroid therapy and sex showed mixed associations, while parenchymal lung involvement was not linked to increased OSA risk in any study.
conclusionThe prevalence of OSA in people with sarcoidosis is high. Conventional risk factors for OSA, including age and BMI, also apply in this group. Further prospective studies with larger, well-defined cohorts are warranted to clarify these associations and explore the potential bidirectional relationship between sarcoidosis and OSA. Studies should expand our knowledge on symptoms and hypoxic burden of subjects with sarcoidosis and OSA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.